OXFENDAZOLE

Details

Stereochemistry	UNKNOWN
Molecular Formula	C15H13N3O3S
Molecular Weight	315.347
Optical Activity	( + / - )
Defined Stereocenters	0 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC(=O)NC1=NC2=C(N1)C=C(C=C2)[S+]([O-])C3=CC=CC=C3

InChI

InChIKey=BEZZFPOZAYTVHN-UHFFFAOYSA-N

InChI=1S/C15H13N3O3S/c1-21-15(19)18-14-16-12-8-7-11(9-13(12)17-14)22(20)10-5-3-2-4-6-10/h2-9H,1H3,(H2,16,17,18,19)

HIDE SMILES / InChI

Molecular Formula	C15H13N3O3S
Molecular Weight	315.347
Charge	0
Count

Stereochemistry	ACHIRAL
Additional Stereochemistry	No
Defined Stereocenters	0 / 0
E/Z Centers	0
Optical Activity	NONE

Description
Sources: https://www.drugs.com/international/oxfendazole.html | https://www.ncbi.nlm.nih.gov/pubmed/23936558

Oxfendazole is a broad spectrum benzimidazole anthelmintic. Oxfendazole has broad-spectrum activity against inhibited larval stages of gastrointestinal roundworms, tapeworms, and lungworms in many animal species at doses between 4.5–10 mg/kg.

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Acetylcholinesterase, Nippostrongylus brasiliensis 1 Target ID: Acetylcholinesterase, Nippostrongylus brasiliensis Sources: https://www.ncbi.nlm.nih.gov/pubmed/7150334 \| https://www.ncbi.nlm.nih.gov/pubmed/7322189	Inhibitor 8504
Tubulin alpha chain 3 Target ID: P50719 Gene ID: NA Gene Symbol: NA Target Organism: Haemonchus contortus (Barber pole worm) Sources: https://www.ncbi.nlm.nih.gov/pubmed/1889474	Binding Agent 1076		266.0 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Helminthiasis in cattle 3 Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=152cde64-ff22-4a3e-bb78-65e159dbe6b6	Curative	Approved 8583	Synanthic Bovine Dewormer Approved Use Oxfendazole is indicated for use in cattle (excluding female dairy cattle of breeding age) for the removal and control of: Lungworms (Dictyocaulus viviparus): Adult, L-4. Stomach worms: Barberpole worms (Haemonchus contortus and H. placei): Adult. Brown stomach worms (Ostertagia ostertagi): Adult, L-4, and inhibited L-4 larvae. Small stomach worms(Trichostrongylus axei): Adult. Intestinal worms: Hookworms (Bunostomum phlebotomum): Adult. Small intestinal worm (Cooperia punctata, C. oncophora and C. mcmasteri): Adult, L-4. Tapeworms (Moniezia benedeni): Adult. Nodular worms (Oesophagostomum radiatum): Adult. Launch Date 1993
Neurocysticercosis 2 Sources: https://clinicaltrials.gov/ct2/show/NCT02234570	Primary	Phase I 438	Unknown Approved Use Unknown
Helminthiasis 39 Sources: https://clinicaltrials.gov/ct2/show/NCT02636803	Curative	Phase II 1147	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
944 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
1160 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
2440 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
4780 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	7.5 mg/kg single, oral dose: 7.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
6250 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
5300 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
6770 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
2960 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4160 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	7.5 mg/kg single, oral dose: 7.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5990 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
3010 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
4500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
3500 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg 1 times / day steady-state, oral dose: 3 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
5980 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	7.5 mg/kg 1 times / day steady-state, oral dose: 7.5 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
6000 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	15 mg/kg 1 times / day steady-state, oral dose: 15 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

AUC

Value	Dose	Analyte	Population
11700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
13100 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
30800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
73700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	7.5 mg/kg single, oral dose: 7.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
99500 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
78300 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
109000 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
30200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
52500 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	7.5 mg/kg single, oral dose: 7.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
79200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
34800 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
65400 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
38200 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg 1 times / day steady-state, oral dose: 3 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
65700 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	7.5 mg/kg 1 times / day steady-state, oral dose: 7.5 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
69600 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	15 mg/kg 1 times / day steady-state, oral dose: 15 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

T_1/2

Value	Dose	Analyte	Population
9.07 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	0.5 mg/kg single, oral dose: 0.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
8.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	1 mg/kg single, oral dose: 1 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
10.3 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
9.59 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	7.5 mg/kg single, oral dose: 7.5 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
9.97 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	15 mg/kg single, oral dose: 15 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
9.82 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	30 mg/kg single, oral dose: 30 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED
11 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/30745383/	60 mg/kg single, oral dose: 60 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
7.65 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
8.05 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg single, oral dose: 3 mg/kg route of administration: Oral experiment type: SINGLE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: HIGH-FAT
9.21 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	3 mg/kg 1 times / day steady-state, oral dose: 3 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
10.5 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	7.5 mg/kg 1 times / day steady-state, oral dose: 7.5 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED
11.8 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/32816721/	15 mg/kg 1 times / day steady-state, oral dose: 15 mg/kg route of administration: Oral experiment type: STEADY-STATE co-administered:	OXFENDAZOLE plasma	Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED

Doses

Dose	Population	Adverse events
60 mg/kg single, oral Highest studied dose Dose: 60 mg/kg Route: oral Route: single Dose: 60 mg/kg Sources: https://pubmed.ncbi.nlm.nih.gov/30745383/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: FASTED Sources: https://pubmed.ncbi.nlm.nih.gov/30745383/	Sources: https://pubmed.ncbi.nlm.nih.gov/30745383/
15 mg/kg 1 times / day multiple, oral Studied dose Dose: 15 mg/kg, 1 times / day Route: oral Route: multiple Dose: 15 mg/kg, 1 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/32816721/	healthy, ADULT Health Status: healthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: https://pubmed.ncbi.nlm.nih.gov/32816721/	Sources: https://pubmed.ncbi.nlm.nih.gov/32816721/

Overview

CYP3A4	CYP2C9	CYP2D6	hERG
inhibitor 2252	inhibitor 2438	inhibitor 2507	inhibitor 2217

OverviewOther

Other Inhibitor	Other Substrate	Other Inducer
CYP1A2 2153 CYP2A6 879 CYP2E1 1060 CYP2C19 2057 BCRP 910 OATP1B3 961 CYP19A1 429 OATP1B1 1079	P-gp 2052 MRP2 252 BCRP 697

Drug as perpetrator

Target	Modality	Activity
CYP3A4 2633	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDI0NDIifX0=	inconclusive [IC50 2.5119 uM]
CYP1A2 2333	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzU2IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	no [IC50 >10 uM]
CYP2A6 911	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	no [IC50 >10 uM]
CYP2C19 2141	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzNjIyIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	no [IC50 >10 uM]
CYP2C9 2497	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwzMzk3IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	no [IC50 >10 uM]
CYP2D6 2546	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyODkiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDI0NDIifX0=	no [IC50 >10 uM]
CYP2E1 1146	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MjgxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	no [IC50 >10 uM]
BCRP 985	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkw1MzkzIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	no
CYP19A1 430	inhibitor 4027 Sources: https://pubchem.ncbi.nlm.nih.gov/compound/40854#section=Biological-Test-Results Page: 244.0	no
OATP1B1 1095	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNjk3NjY4IiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	yes [Inhibition 10 uM]
OATP1B3 970	inhibitor 4027 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwxNzQzMTIxIiwidXNlX2N1c3RvbV9xdWVyeSI6dHJ1ZSwic2VhcmNoX3Rlcm0iOiIiLCJ0ZXh0X2ZpbHRlciI6IkNIRU1CTDQyNDQyIn19	yes [Inhibition 10 uM]

Drug as victim

Target	Modality	Activity
BCRP 697	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15703302/	moderate
MRP2 252	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15703302/	no
P-gp 2052	substrate 4014 Sources: https://pubmed.ncbi.nlm.nih.gov/15703302/	no

Tox targets

Target	Modality	Activity	Metabolite	Clinical evidence
hERG 2263	inhibitor 2237 Sources: https://www.ebi.ac.uk/chembl/g/#browse/activities/full_state/eyJsaXN0Ijp7InNldHRpbmdzX3BhdGgiOiJFU19JTkRFWEVTX05PX01BSU5fU0VBUkNILkFDVElWSVRZIiwiY3VzdG9tX3F1ZXJ5IjoidGFyZ2V0X2NoZW1ibF9pZDpDSEVNQkwyNDAiLCJ1c2VfY3VzdG9tX3F1ZXJ5Ijp0cnVlLCJzZWFyY2hfdGVybSI6IiIsInRleHRfZmlsdGVyIjoiQ0hFTUJMNDI0NDIifX0=

PubMed

Title	Date	PubMed
Disruption of spindle checkpoint function ahead of facilitation of cell proliferation by repeated administration of hepatocarcinogens in rats.	2015-12	26558467
Investigating effects of parasite infection on body condition of the Kafue lechwe (Kobus leche kafuensis) in the Kafue basin.	2010-12-23	21182793
The gastrointestinal nematode Trichostrongylus colubriformis down-regulates immune gene expression in migratory cells in afferent lymph.	2010-10-17	20950493
In vitro Effects of Albendazole on Raillietina echinobothrida, the Cestode of Chicken, Gallus domesticus.	2010-10	21264097
Eradication of Taenia solium cysticercosis: a role for vaccination of pigs.	2010-08-15	20470777
Interaction of anthelmintic drugs with P-glycoprotein in recombinant LLC-PK1-mdr1a cells.	2010-08-05	20513441
Anthelmintic resistance of Ostertagia ostertagi and Cooperia oncophora to macrocyclic lactones in cattle from the western United States.	2010-06-24	20347229
Association of two single-isomer anionic CD in NACE for the chiral and achiral separation of fenbendazole, its sulphoxide and sulphone metabolites: application to their determination after in vitro metabolism.	2010-05	20376816
Elimination of Taenia solium transmission to pigs in a field trial of the TSOL18 vaccine in Cameroon.	2010-04	20138046
Multiple anthelmintic resistance and the possible contributory factors in Beetal goats in an irrigated area (Pakistan).	2010-04	19733870
Evaluation of oxfendazole, praziquantel and albendazole against cystic echinococcosis: a randomized clinical trial in naturally infected sheep.	2010-02-23	20186332
Unchanged triclabendazole kinetics after co-administration with ivermectin and methimazole: failure of its therapeutic activity against triclabendazole-resistant liver flukes.	2010-02-03	20128898
Antioxidant enzymatically modified isoquercitrin or melatonin supplementation reduces oxidative stress-mediated hepatocellular tumor promotion of oxfendazole in rats.	2010-02	20033131
Fecal egg count reduction and control trial determinations of anthelmintic efficacies for several parasiticides utilizing a single set of naturally infected calves.	2009-10-14	19615822
Comparative assessment of albendazole and triclabendazole ovicidal activity on Fasciola hepatica eggs.	2009-10-14	19560276
Anthelminthic resistance of Haemonchus contortus in small ruminants in Switzerland and Southern Germany.	2009-10	19915817
Equine cyathostomins: a review of biology, clinical significance and therapy.	2009-09-25	19778462
Simultaneous determination of five benzimidazoles in feeds using high-performance capillary electrophoresis.	2009-09-01	19714965
Enantiomeric behaviour of albendazole and fenbendazole sulfoxides in domestic animals: pharmacological implications.	2009-09	19124257
Efficacy of an injectable combination anthelmintic (nitroxynil+clorsulon+ivermectin) against early immature Fasciola hepatica compared to triclabendazole combination flukicides given orally or topically to cattle.	2009-06-10	19375232
The potential to control Haemonchus contortus in indigenous South African goats with copper oxide wire particles.	2009-06-10	19346076
Efficacy against Fasciola hepatica and the pharmacokinetics of triclabendazole administered by oral and topical routes.	2009-05	19382929
Involvement of oxidative stress in hepatocellular tumor-promoting activity of oxfendazole in rats.	2009-05	18754104
Haemonchus contortus acetylcholine receptors of the DEG-3 subfamily and their role in sensitivity to monepantel.	2009-04	19360096
Evaluation of nitazoxanide and oxfendazole efficacy against cystic echinococcosis in naturally infected sheep.	2009-03	19270283
The old and new therapeutic approaches to the treatment of giardiasis: where are we?	2009	19707415
Taenia solium porcine cysticercosis: viability of cysticerci and persistency of antibodies and cysticercal antigens after treatment with oxfendazole.	2008-11-25	18834668
Comprehensive screening and quantification of veterinary drugs in milk using UPLC-ToF-MS.	2008-07	18491081
UMF-078: A modified flubendazole with potent macrofilaricidal activity against Onchocerca ochengi in African cattle.	2008-06-20	18570639
Prevalence of multiple anthelmintic resistant gastrointestinal nematodes in dairy goats in a desolated tract (Pakistan).	2008-06	18301923
Lungworm infection in three loggerhead sea turtles, Caretta caretta.	2008-03	18432101
[The investigation of short term efficiency of oxfendazole + oxyclozanide paste and tablet formulations against gastrointestinal nematodes in sheep].	2008	18645944
Comparative plasma disposition of fenbendazole, oxfendazole and albendazole in dogs.	2007-09-30	17673370
Gene expression analyses of the liver in rats treated with oxfendazole.	2007-09	17340121
Glossitis and tongue trauma subsequent to administration of an oral medication, using an udder infusion cannula, in a horse.	2007-08	17824329
Study (1991 to 2001) of drug-resistant Population B small strongyles in critical tests in horses in Kentucky at the termination of a 40-year investigation.	2007-08	17468973
A screening level index for assessing the impacts of veterinary medicines on dung flies.	2007-04-01	17438826
A survey of anthelmintic use and internal parasite control in farmed deer in New Zealand.	2007-04	17410216
Efficacy of oxfendazole and fenbendazole against tortoise (Testudo hermanni) oxyurids.	2007-04	17120044
Fecal egg count reductions and performance effect of Dectomax, Cydectin, and Cydectin plus Synanthic as used in feedlot steers.	2007	18183550
Selective and on-demand drenching of lambs: impact on parasite populations and performance of lambs.	2006-12	17151729
Evaluation of broad-spectrum anthelmintic activity in a novel assay against Haemonchus contortus, Trichostrongylus colubriformis and T. sigmodontis in the gerbil Meriones unguiculatus.	2006-12	17125549
Survey of parasite control on beef farms in south-west England.	2006-11-11	17099179
[Thoracic hydatid cysts: news].	2006-09	17127973
[Imported coenurosis in sheep].	2006-09	17024978
Ecological hazard assessment of major veterinary benzimidazoles: acute and chronic toxicities to aquatic microbes and invertebrates.	2006-08	16916042
Enantiomeric separation of chiral sulfoxides by supercritical fluid chromatography.	2006-07	16894780
Plasma disposition and faecal excretion of oxfendazole, fenbendazole and albendazole following oral administration to donkeys.	2006-07	16772142
In vitro susceptibilities of the AIDS-associated microsporidian Encephalitozoon intestinalis to albendazole, its sulfoxide metabolite, and 12 additional benzimidazole derivatives.	1997-12	9420047
In vitro susceptibility of the opportunistic fungus Cryptococcus neoformans to anthelmintic benzimidazoles.	1994-02	8192471

Patents

Sample Use Guides

In Vivo Use Guide

Cattle: The recommended dose for cattle is 2.05 mg/lb (4.5 mg/kg) of body weight. Synanthic Bovine Dewormer Suspension, 22.5%, should be administered orally by accurate dose syringe at the rate of 1 mL per 110 lb (50 kg) of body weight.

Route of Administration: Oral

In Vitro Use Guide

0.1 mM oxfendazole inhibited acetylcholinesterase secretion from Nippostrongylus brasiliensis in vitro.

Substance Class	Chemical Created by `admin` on `Mon Mar 31 17:52:39 GMT 2025` Edited by `admin` on `Mon Mar 31 17:52:39 GMT 2025`
Record UNII	OMP2H17F9E
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

OXFENDAZOLE

Official Name

English

SYNANTHIC

Preferred Name

English

OXFENDAZOLE [USAN]

Common Name

English

OXFENDAZOLE [USP MONOGRAPH]

Common Name

English

oxfendazole [INN]

Common Name

English

CARBAMIC ACID, 5-(PHENYLSULFINYL)-1H-BENZIMIDAZOL-2-YL-, METHYL ESTER

Common Name

English

OXFENDAZOLE [MART.]

Common Name

English

OXFENDAZOLE [GREEN BOOK]

Common Name

English

RS-8858

Code

English

OXFENDAZOLE [MI]

Common Name

English

NSC-758943

Code

English

Methyl 5-(phenylsulfinyl)-2-benzimidazolecarbamate

Common Name

English

OXFENDAZOLE [USP-RS]

Common Name

English

Classification Tree Code System Code

CFR

21 CFR 556.495